WuXi News

Filter By


WuXi AppTec China Sites Resume Operations after Extended Lunar New Year Holiday

SHANGHAI, February 12, 2020 - With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site in Wuhan, which will reopen when local regulations permit. These steps are being taken in compliance with disease control guidelines pertaining to the coronavirus outbreak and with the utmost attention to the health and safety of our employees and their families.

Read more


WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

January 13, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

Read more


WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. This significant milestone marks WuXi STA’s establishment of a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial. It enables customers around the world to advance promising new oligonucleotide therapies more rapidly to market for the benefit of patients.

Read more


WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products

Shanghai and Seoul, November 29, 2019 - WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the development and manufacturing of oncolytic virus products. Under the terms of the collaboration, WuXi ATU will provide overall process development, manufacturing and Investigational New Drug (IND) filing services for GeneMedicine’s oncolytic virus products.

Read more


WuXi AppTec's Lab Testing Division Expands Toxicology Facility in Suzhou, China

SHANGHAI, Nov. 18, 2019 - WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced its Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global customers’ preclinical testing needs and enable them to accelerate the development timelines and bring innovative medicines to patients faster.

Read more